CUSIP: 68827R108
Q4 2018 13F Holders as of 31 Dec 2018
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
3,362,560
-
Share change
-
+679,736
-
Total reported value
-
$45,395,000
-
Price per share
-
$13.50
-
Number of holders
-
43
-
Value change
-
+$9,266,357
-
Number of buys
-
25
-
Number of sells
-
8
Quarterly Holders Quick Answers
What is CUSIP 68827R108?
CUSIP 68827R108 identifies OSIR - OSIRIS THERAPEUTICS INC NEW - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2019
-
Previous quarter:
Q3 2018
Recent filing periods for CUSIP 68827R108:
Institutional Holders of OSIRIS THERAPEUTICS INC NEW - COM (OSIR) as of Q4 2018
As of 31 Dec 2018,
OSIRIS THERAPEUTICS INC NEW - COM (OSIR) was held by
43 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
3,362,560 shares.
The largest 10 holders included
Vanguard Group Inc, Cloverdale Capital Management, LLC, GABELLI FUNDS LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, MANUFACTURERS LIFE INSURANCE COMPANY, THE, GEODE CAPITAL MANAGEMENT, LLC, NORTHERN TRUST CORP, QS Investors, LLC, EAM Global Investors LLC, and GAMCO INVESTORS, INC. ET AL.
This page lists
43
institutional shareholders reporting positions in this security
for the Q4 2018 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.